Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 17/20 | 0.56 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.56 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.56 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.56 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15261629 | 1.00 | LPAR1 (0.56) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL14710758 | 0.91 | LPAR1 (0.57) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL9899815 | 0.89 | LPAR1 (0.67) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL9899811 | 0.89 | LPAR1 (0.67) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL14790487 | 0.88 | LPAR1 (0.58) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL9899860 | 0.83 | KCNA3 (0.46) | KCNA3OPRM1 | |
| SCHEMBL14790488 | 0.83 | LPAR1 (0.51) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL8005 | 0.83 | LPAR1 (0.82) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL1325246 | 0.83 | LPAR1 (0.82) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL8006 | 0.83 | LPAR1 (0.82) | LPAR1ABCC3ABCC4ABCB11CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272990-B2 | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | AMIRA PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9272990-B2 | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | AMIRA PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2648714-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2648714-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | AMIRA PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | AMIRA PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012078593-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | LPAR2, LPAR1, LPAR4 | LPAR1 2/4885ABCC3 2770/4885ABCC4 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.